Genmab shares rise 8% as AbbVie’s combination therapy confirms reduced risk of death

智通财经2026/10/06 07:21

Show original

Genmab shares rose by 8% after its blood cancer drug combination, developed in collaboration with AbbVie, was shown to reduce the risk of death.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

The U.S. Department of Energy authorizes the Strategic Petroleum Reserve to swap up to 4 million barrels of crude oil.

智通财经•2026/10/10 19:46

ExxonMobil and BP can allocate up to 2 million barrels of crude oil between each other

智通财经•2026/10/10 19:46

The U.S. Department of Energy launches emergency crude oil exchange mechanism to stabilize energy supply

智通财经•2026/10/10 19:46

Nvidia reportedly in talks to acquire or increase investment in Reflection AI

智通财经•2026/10/10 18:41